Cancers, Vol. 12, Pages 869: Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma

Cancers, Vol. 12, Pages 869: Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma Cancers doi: 10.3390/cancers12040869 Authors: Tashbib Khan Yaowu He Thomas Kryza Brittney S. Harrington Jennifer H. Gunter Mitchell A. Sullivan Tahleesa Cuda Rebecca Rogers Claire M. Davies Amy Broomfield Madeline Gough Andy C. Wu Thomas McGann S. John Weroha Paul Haluska Josephine M. Forbes Jane E. Armes Sinead C. Barry Jermaine I. Coward Nisha Jagasia Naven Chetty Cameron E. Snell Rohan Lourie Lewis C. Perrin John D. Hooper High stage and recurrent ovarian clear cell carcinoma (OCC) are associated with poor prognosis and resistance to chemotherapy. A distinguishing histological feature of OCC is abundant cytoplasmic stores of glucose, in the form of glycogen, that can be mobilized for cellular metabolism. Here, we report the effect on preclinical models of OCC of disrupting glycogen utilization using the glucose analogue 2-deoxy-D-glucose (2DG). At concentrations significantly lower than previously reported for other cancers, 2DG markedly improves the efficacy in vitro of carboplatin chemotherapy against chemo-sensitive TOV21G and chemo-resistant OVTOKO OCC cell lines, and this is accompanied by the depletion of glycogen. Of note, 2DG doses—of more than 10-fold lower than previously reported for other cancers—significantly im...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research